Drug Profile
Research programme: CD3-CD123 bispecific antibodies - Sanofi
Alternative Names: CD123 CODV TCELatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in France
- 21 Apr 2018 Pharmacodynamics and pharmacokinetics data from a preclinical study in Acute myeloid leukaemia presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 09 Apr 2018 Preclinical trials in Acute myeloid leukaemia in France (unspecified route)